This Stock Reminds Me of AMD in 2025
1 extracted signal · 0 resolved · 1 still active
The Patient InvestorIndependent analyst profile- Source published
- 02 Sept 2026, 18:23 UTC
- Recorded by Tahlil Plus
- 02 Sept 2026, 20:12 UTC

AI-generated source summary
The analysis focuses on QUALCOMM (QCOM), identifying a significant opportunity for growth driven by their AI accelerator technology and the increasing demand in data centers. Despite a recent earnings report showing a 4% year-over-year decline in revenue, primarily due to a 20% drop in handset chip sales, the company's automotive and IoT segments showed strong growth of 61% and 9% respectively. The core thesis is that QUALCOMM's non-handset revenue, particularly from the data center segment, is projected to accelerate significantly, with forecasts indicating a rise from 24% in FY26 to 60%+ in FY27. Analysts suggest that this growth could offset the decline in handset revenue, with a target of non-handset revenue replacing total Apple product revenues in FY26 and expanding to $15B+ by FY29. The company's strategy involves leveraging its advanced High Bandwidth Compute (HBC) technology, which offers superior performance per watt and lower energy consumption compared to High Bandwidth Memory (HBM). This technology is being deployed in AI infrastructure and is expected to drive significant improvements in cost and performance. The stock is currently trading at a forward P/E of approximately 18x, which is considered reasonable given the growth prospects. The analysis estimates a potential upside of roughly 100% over the next three years, projecting earnings per share to exceed $18 in FY29. The current market sentiment appears to be underestimating QUALCOMM's potential in the data center and AI space, creating a potentially undervalued investment opportunity.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
